Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 56, Issue 4, 2011, Pages 595-603

  Kolb, E Anders ^a   Gorlick, Richard ^b   Lock, Richard ^c   Carol, Hernan ^c   Morton, Christopher L ^d   Keir, Stephen T ^e   Reynolds, C Patrick ^f   Kang, Min H ^f   Maris, John M ^g   Billups, Catherine ^d   Smith, Malcolm A ^h   Houghton, Peter J ⁱ  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Developmental therapeutics; IGF 1 receptor inhibitor; Preclinical testing

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 754807; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; EWING SARCOMA; FEMALE; IN VITRO STUDY; MOUSE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA CELL; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHILD; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS; PYRAZOLES; RECEPTOR, IGF TYPE 1; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551630554     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22741     Document Type: Article

References (45)

1. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 2009; 28: 3009-3021.
2. Rikhof B, de Jong S, Suurmeijer AJ, et al. The insulin-like growth factor system and sarcomas. J Pathol 2009; 217: 469-482.
3. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 2009; 11: 307-313.
4. Hermanto U, Zong CS, Wang LH. Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. Cell Growth Differ 2000; 11: 655-664.
5. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006; 1766: 1-22.
6. Kim SY, Toretsky JA, Scher D, et al. The role of IGF-1R in pediatric malignancies. Oncologist 2009; 14: 83-91.
7. Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 2009; 69: 2443-2452.
8. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007; 67: 391-397.
9. Carboni JM, Wittman M, Yang Z, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009; 8: 3341-3349.
10. Wittman MD, Carboni JM, Yang Z, et al. Discovery of a 2, 4-disubstituted pyrrolo[1, 2-f][1, 2, 4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J Med Chem 2009; 52: 7360-7363.
11. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
12. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 37-45.
13. Hailey J, Maxwell E, Koukouras K, et al. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002; 1: 1349-1353.
14. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-4195.
15. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
16. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
17. Pollak M, Richard M. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 1990; 82: 1349-1352.
18. Bostedt KT, Schmid C, Ghirlanda-Keller C, et al. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Exp Cell Res 2001; 271: 368-377.
19. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004; 92: 77-91.
20. El-Badry OM, Helman LJ, Chatten J, et al. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest 1991; 87: 648-657.
21. Weber A, Huesken C, Bergmann E, et al. Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas. Clin Cancer Res 2003; 9: 5683-5692.
22. Sandberg AC, Engberg C, Lake M, et al. The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. Neurosci Lett 1988; 93: 114-119.
23. Resnicoff M, Li W, Basak S, et al. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother 1996; 42: 64-68.
24. Antoniades HN, Galanopoulos T, Neville-Golden J, et al. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992; 50: 215-222.
25. Del Valle L, Enam S, Lassak A, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002; 8: 1822-1830.
26. Hirschfeld S, Helman L. Diverse roles of insulin-like growth factors in pediatric solid tumors. In Vivo 1994; 8: 81-90.
27. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35: 685-693.
28. Gidding CE, Germain GS, Dilling MB, et al. The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models. Cancer Chemother Pharmacol 2000; 45: 21-30.
29. Thimmaiah KN, Easton J, Huang S, et al. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res 2003; 63: 364-374.
30. Fukuzawa R, Umezawa A, Ochi K, et al. High frequency of inactivation of the imprinted H19 gene in "sporadic" hepatoblastoma. Int J Cancer 1999; 82: 490-497.
31. Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998; 58: 4127-4131.
32. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res 1996; 56: 4570-4574.
33. de Alava E, Panizo A, Antonescu CR, et al. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000; 156: 849-855.
34. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24: 7275-7283.
35. Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998; 69: 21-27.
36. Pollak M, Sem AW, Richard M, et al. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992; 84: 966-971.
37. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1190-1197.
38. Vorwerk P, Wex H, Hohmann B, et al. Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia. Mol Pathol 2002; 55: 40-45.
39. Kolb EA, Morton C, Houghton PJ, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the fully human anti-IGF-1R antibody IMC-A12. Eur J Cancer Suppl 2008; 6: 176 (Abstr #558).
40. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1190-1197.
41. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010; 54: 921-926.
42. Carden CP, Molife LR, de Bono JS. Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. Mol Cancer Ther 2009; 8: 2077-2078.
43. Huang F, Greer A, Hurlburt W, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009; 69: 161-170.
44. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, et al. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: Rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009; 15: 5445-5456.
45. Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008; 68: 1538-1545.